Top Markets
#1 Nesa Nesa +820.50%
#2 Cortex Cortex +68.91%
#3 Kinesis Silver Kinesis Silver +57.40%
#4 Merlin's Seal BTC Merlin's Seal BTC +45.66%
#5 QuantixAI QuantixAI +24.05%
#6 EXOD EXOD +22.78%
#7 Cash Cat Cash Cat +20.46%
#8 OpenEden OpenEden +19.61%
#9 Palladium Network Palladium Network +18.94%
#10 Instadapp Instadapp +16.15%
Coin of the day
Nesa Nesa
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Molecular Partners AG Molecular Partners AG

Molecular Partners AG

MOLN
Classificação em ações #19281
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Preço da ação
$4.51
Valor de mercado
$169.29M
Variação (1 dia)
1.76%
Variação (1 ano)
23.78%
País
CH
Negociar Molecular Partners AG (MOLN)

Categoria

Healthcare
Rácio P/B de Molecular Partners AG (MOLN)
Rácio P/B em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Molecular Partners AG, o rácio P/B atual (TTM) é 0. No final de 2026, o rácio P/B era 0.
Histórico do rácio P/B da Molecular Partners AG de 2026 a 2026
Rácio P/B no final de cada ano
Ano Rácio P/B Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/B de empresas semelhantes ou concorrentes
Empresa Rácio P/B Diferença do rácio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH